120. Benign Ethnic Neutropenia in a Sample of Nigerian Healthy Controls and Clozapine-Treated Schizophrenia Patients With DARC Null Variant
Ikwunga Wonodi(University of Maryland, Baltimore), Deanna L. Kelly(University of Maryland, Baltimore), Gopal Vyas(University of Maryland, Baltimore), Adeola Adebayo(Federal Neuro Psychiatric Hospital), Isiaka Amoo(Federal Neuro Psychiatric Hospital), Titilope Adebimpe(Federal Neuro Psychiatric Hospital), Ayodeji Olaniyan(Federal Neuro Psychiatric Hospital), Richard A. Adebayo(Federal Neuro Psychiatric Hospital), Taiwo Oduguwa(Federal Neuro Psychiatric Hospital), Charles Richardson(Los Alamos National Laboratory), Olufunto Olufela Kalejaiye(Federal Neuro Psychiatric Hospital), Matthew Glassman(University of Maryland, Baltimore), R A Lawal(Federal Neuro Psychiatric Hospital), Olawunmi Peters(Federal Neuro Psychiatric Hospital)
Cited by 5
Related Papers
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
|Schizophrenia Bulletin|2009|915
Olanzapine Compared With Chlorpromazine in Treatment-Resistant Schizophrenia
|American Journal of Psychiatry|1998|245
Clozapine Underutilization and Discontinuation in African Americans Due to Leucopenia
|Schizophrenia Bulletin|2006|103
Megacystis-microcolon-intestinal hypoperistalsis syndrome and the absence of the α3 nicotinic acetylcholine receptor subunit
|Gastroenterology|2001|98
Role of smoking in inflammatory bowel disease: implications for therapy
|Postgraduate Medical Journal|2000|88